

Table of contents

Preface	V
Authors	VII

PART I EUROPE

§ 1. Overview

A. Skinny labelling of generic and biosimilar products in the European Union ..	1
I. Generics	2
II. Biosimilars	3
B. Protection of second medical use claims under the European Patent Convention	3

§ 2. Austria

A. Executive summary	5
B. Scope of protection and interpretation of second medical use claims	5
C. Direct and indirect infringement of second medical use claims	6
I. Direct patent infringement	6
II. Indirect patent infringement	7
D. Infringement of second medical use claims and skinny label products	8
E. Infringement of second medical use claims and biosimilar products	9
F. Strategies and considerations	9
G. Legal remedies	9
H. Statutory provisions	10
J. Extracts from court decisions	11

§ 3. Denmark

A. Executive summary	27
B. Scope of protection and interpretation of second medical use claims	27
C. Direct and indirect infringement of second medical use claims	28
I. Direct patent infringement	28
II. Indirect patent infringement	29
D. Infringement of second medical use claims and skinny label products	30
E. Infringement of second medical use claims and biosimilar products	31
F. Strategies and considerations	33
G. Legal remedies	33
H. Statutory provisions	35
J. Extract from court decision	42

§4. France

A. Executive summary	44
B. Scope of protection and interpretation of second medical use claims	44
C. Direct and indirect infringement of second medical use claims	45
I. Direct patent infringement	45
1. Direct infringement of second medical use claims in general	45
2. Direct infringement of second medical use claims by equivalence of means	46
II. Indirect patent infringement	47
D. Infringement of second medical use claims and skinny label products	47
I. Significance of skinny labelling in the assessment of second medical use claims' infringement	47
II. Significance of a prescribing practice in the assessment of second medical use claims' infringement	49
E. Infringement of second medical use claims and biosimilar products	50
F. Strategies and considerations	51
G. Legal remedies	51
H. Statutory provisions	52
J. Extracts from court decisions	55

§5. Germany

A. Executive summary	67
B. Scope of protection and interpretation of second medical use claims	67
C. Direct and indirect infringement of second medical use claims	68
I. Direct patent infringement	68
1. Purposeful preparation	68
2. Preparation-free liability	69
II. Indirect patent infringement	70
D. Infringement of second medical use claims and skinny label products	71
E. Infringement of second medical use claims and biosimilar products	72
F. Strategies and considerations	74
G. Legal remedies	75
H. Statutory provisions	76
J. Extracts from court decisions	81

§6. Ireland

A. Executive summary	86
B. Scope of protection and interpretation of second medical use claims	86
C. Direct and indirect infringement of second medical use claims	87
I. Direct patent infringement	87
II. Indirect patent infringement	88
D. Infringement of second medical use claims and skinny label products	88
E. Infringement of second medical use claims and biosimilar products	89
F. Strategies and considerations	89
G. Legal remedies	90
H. Statutory provisions	91
J. Extracts from court decisions	95

§ 7. Italy

A. Executive summary	96
B. Scope of protection and interpretation of second medical use claims	96
C. Direct and indirect infringement of second medical use claims	97
I. Infringement of second medical use claims – direct patent infringement	97
II. Indirect patent infringement	99
D. Infringement of second medical use claims and skinny label products	100
E. Strategies and considerations	100
F. Legal remedies	101
G. Infringement of second medical use claims and biosimilar products	102
H. Statutory provisions	103
J. Extracts from court decisions	104

§ 8. The Netherlands

A. Executive summary	111
B. Scope of protection and interpretation of second medical use claims	111
C. Direct and indirect infringement of second medical use claims	112
I. Direct patent infringement	113
II. Indirect patent infringement	113
1. <i>Sun/Novartis</i>	113
2. <i>MSD/Teva</i>	114
D. Infringement of second medical use claims and skinny label products	115
I. Off-label prescribing in the Netherlands	116
E. Infringement of second medical use claims and biosimilar products	118
F. Strategies and considerations	119
I. Carve out	119
II. Carve in	120
III. Effective measures	120
G. Legal remedies	121
I. Trigger for (threat of) infringement	121
II. Legal remedies available to patentee	122
1. Preliminary injunction proceedings (<i>inter partes</i>)	122
2. Proceedings on the merits	122
3. <i>Ex parte</i> injunction	123
H. Statutory provisions	123
J. Extracts from court decisions	126

§ 9. Poland

A. Executive summary	131
B. Scope of protection and interpretation of second medical use claims	131
C. Direct and indirect infringement of second medical use claims	132
I. Product limited by purpose	132
II. Swiss-type claims	134
III. Swiss-type and product-by-use claims – scope of protection	135
IV. Direct v indirect infringement. Indirect/supplementary protection under general civil law/unfair competition law	135
D. Infringement of second medical use claims and skinny label products	136
E. Infringement of second medical use claims and biosimilar products	137

F. Strategies and considerations	138
G. Legal remedies	139
H. Statutory provisions	141
J. Extracts from court decisions	143

§ 10. Portugal

A. Executive summary	146
B. Scope of protection and interpretation of second medical use claims	146
C. Direct and indirect infringement of second medical use claims	147
D. Infringement of second medical use claims and skinny label products	148
E. Infringement of second medical use claims and biosimilar products	149
F. Strategies and considerations	149
G. Legal remedies	150
H. Statutory provisions	150
J. Extracts from court decisions	157

§ 11. Spain

A. Executive summary	160
B. Scope of protection and interpretation of second medical use claims	161
C. Direct and indirect infringement of second medical use claims	164
D. Infringement of second medical use claims and skinny label products	165
I. Madrid courts – <i>Venlafaxine</i> (2006–2010)	165
II. Barcelona courts – <i>Pregabalin</i> (2015–2016)	167
E. Infringement of second medical use claims and biosimilar products	168
F. Strategies and considerations	169
G. Legal remedies	169
H. Statutory provisions	170
J. Extracts from court decisions	177
I. General decisions on medical use claims	177
II. Specific decisions on skinny labelling	182

§ 12. Türkiye

A. Executive summary	188
B. Scope of protection and interpretation of second medical use claims	189
C. Direct and indirect infringement of second medical use claims	189
I. Direct infringement	189
II. Indirect infringement	190
D. Infringement of second medical use claims and skinny label products	192
E. Infringement of second medical use claims and biosimilar products	194
F. Strategies and considerations	195
G. Legal remedies	196
H. Statutory provisions	198
J. Extracts from court decisions	203
I. Infringement of second medical use patent for literal infringement and infringement under doctrine of equivalents	203
II. Patentability of second medical use patent	204
III. Indirect use	205

§ 13. United Kingdom

A. Executive summary	207
B. Scope of protection and interpretation of second medical use claims	207
C. Direct and indirect infringement of second medical use claims	208
I. Bringing an infringement claim	208
II. Direct patent infringement	208
III. Indirect patent infringement	209
D. Infringement of second medical use claims and skinny label products	211
E. Infringement of second medical use claims and biosimilar products	211
F. Strategies and considerations	212
G. Legal remedies	212
I. Injunctions	212
II. Damages	213
H. Statutory provisions	214
J. Extracts from court decision	214

§ 14. European Unified Patent Court and Unitary Patent

A. Introduction to the new European system	219
B. Structure of the UPC	219
I. The Court of First Instance	220
1. Central Division	220
2. Local and Regional Divisions	220
II. Court of Appeal	221
C. Jurisdiction	221
D. Direct and indirect infringement under the UPC	223
E. Applicable law regarding infringement of second-medical-use patents and cross-label-use	224
F. Skinny label under UPC: a delicate balance	226
G. Procedure and duration of proceedings	226
H. Statutory provisions	227
J. Extracts from court decisions	231

PART II UNITED STATES OF AMERICA

§ 15. United States of America

A. Introduction and executive summary	233
B. Scope of protection and interpretation of second medical use claims	234
I. Legislative background and statutory framework	234
II. Abbreviated new drug applications, the section viii carve-out, and skinny labeling	234
1. The Hatch-Waxman Act and abbreviated new drug applications ..	234
2. The section viii carve out	235
C. Direct and indirect infringement of second medical use claims	236
I. Direct infringement	236
II. Inducement standard, generally	236
D. Infringement of second medical use claims and skinny label products	238

I. Careful generic labeling can usually (but not always) avoid liability for induced infringement	238
II. The Federal Circuit's latest (confusing) pronouncement on skinny labels: <i>GSK v Teva</i>	238
E. Infringement of second medical use claims and biosimilar products	240
I. Legislative background and abbreviated pathway for biosimilars	241
II. Carve-outs in biosimilar skinny labeling	242
F. Strategies and considerations	244
I. Brand strategy for reducing the likelihood of a successful carve-out ..	244
II. Generic strategy for increasing the likelihood of a successful carve-out	244
G. Legal remedies	245
H. Statutory provisions	245
J. Extracts from court decisions	249

PART III AUSTRALIA

§ 16. Australia

A. Executive summary	283
B. Scope of protection and interpretation of second medical use claims	284
I. Method of treatment claims	284
II. Swiss-style claims	284
III. EPC 2000 claims	285
C. Direct and indirect infringement of second medical use claims	286
I. Introduction	286
II. Direct patent infringement	286
1. Infringing acts	286
2. Swiss-type claims	286
a) Products manufactured outside of Australia	286
b) Medicament must be for the specified therapeutic purpose	287
3. EPC 2000 claims	287
III. Indirect patent infringement	288
1. Section 117 Patents Act	288
2. Common law indirect infringement	288
D. Infringement of second medical use claims and skinny label products	289
I. Method of treatment claims	289
1. Relevant cases	289
2. Potential significance of authority prescriptions under PBS	291
II. Swiss-type claims	291
III. EPC 2000 claims	293
E. Infringement of second medical use claims and biosimilar products	293
I. Biosimilar products in Australia	293
II. Patent infringement by biosimilar products	293
F. Strategies and considerations	294
G. Legal remedies	294
I. Interlocutory injunctions	294
II. Permanent injunctions	295
III. Monetary compensation	295
IV. Other remedies	296

H. Statutory provisions	296
J. Extracts from court decisions	297

PART IV ASIA

§ 17. China

A. Executive summary	307
B. Scope of protection and interpretation of second medical use claims	307
C. Direct and indirect infringement of second medical use claims	309
I. Direct infringement	309
II. Indirect infringement	310
D. Infringement of second medical use claims and skinny label products	311
E. Infringement of second medical use claims and biosimilar products	312
F. Strategies and considerations	312
G. Legal remedies	313
I. Administrative remedies	313
II. Judicial remedies	313
H. Statutory provisions	314
I. Provisions about medical use patent	314
II. Provisions about direct infringement	315
III. Provisions about indirect infringement	315
IV. Provisions about legal remedies for infringement	315
J. Extracts from court decisions	319

§ 18. Japan

A. Executive summary	324
B. Scope of protection and interpretation of second medical use claims	324
I. Introduction: skinny labelling of generic and biosimilar products in Japan	324
II. Claim format	326
III. Claim interpretation for second medical use	327
C. Direct and indirect infringement of second medical use claims	328
I. Legal requirement for a patent infringement	328
II. Direct patent infringement	328
III. Indirect Infringement	330
D. Infringement of second medical use claims and skinny label products	331
E. Infringement of second medical use claims and biosimilar products	332
F. Strategies and considerations	333
G. Legal remedies	333
I. Injunction	334
II. Claim for damages	334
III. Claim for unjust enrichment	334
IV. Measures to restore credibility	334
V. Pursuing criminal liability	334
H. Statutory provisions	335
J. Extracts from court decisions	338

§ 19. Singapore

A. Executive summary	342
B. Scope of protection and interpretation of second medical use claims	342
C. Direct and indirect infringement of second medical use claims	344
D. Infringement of second medical use claims and skinny label products	345
I. Labelling requirements	346
II. Patent linkage	346
III. The UK approach to skinny labelling	348
1. Consideration of the subjective intention	348
2. Consideration of the objective intention	348
3. Consideration of the outward presentation	348
E. Infringement of second medical use claims and biosimilar products	349
F. Strategies and considerations	349
G. Legal remedies	349
I. The patent litigation process	350
1. Overview	350
2. Preliminary injunctions and fast-track trials	351
II. Alternative dispute resolution	351
H. Statutory provisions	352
J. Summaries of court decisions	360

§ 20. Taiwan

A. Executive summary	365
B. Scope of protection and interpretation of second medical use claims	365
C. Direct and indirect infringement of second medical use claims	366
D. Infringement of second medical use claims and skinny label products	367
I. <i>AstraZeneca v TSH Biopharm</i>	368
II. <i>Merck Sharp & Dohme Corp. v TSH Biopharm</i>	369
E. Infringement of second medical use claims and biosimilar products	370
F. Strategies and considerations	371
G. Legal remedies	371
I. Constitutive elements of patent infringement	371
1. Objective elements	371
2. Subjective elements	372
II. Remedies in civil litigation	372
III. Limitation	372
IV. Calculation of damages	373
V. Sending warning letters and requesting preservation of evidence:	373
VI. Litigation procedure	373
H. Statutory provisions	374
J. Extracts from court decision	381